Volpara Health Technologies Limited (VPAHF) Stock Analysis

Volpara Health Technologies Limited (VPAHF) Healthcare & Pipeline Overview

Volpara Health Technologies Limited specializes in AI-powered breast imaging analytics software, providing solutions like Volpara Analytics, Live, and Risk to optimize screening operations, assess image quality, and identify high-risk patients. Headquartered in New Zealand, the company serves healthcare providers globally, enhancing early detection and clinical decision-making in breast and lung cancer screening.

What Is the Investment Thesis for VPAHF?

Volpara Health Technologies Limited (VPAHF) operates in the growing medical imaging analytics market, leveraging AI to enhance breast and lung cancer screening efficiency and accuracy. The company's robust gross margin of 76.8% indicates strong unit economics for its software products. Key value drivers include the recurring revenue potential from its subscription-based software model and the increasing adoption of AI in healthcare for improved diagnostic precision. Growth catalysts are anticipated from the expansion of its global footprint across North America, Asia Pacific, Europe, the Middle East, and Africa, coupled with the continuous development of its AI-powered product suite, such as Volpara Science and its specialized clinical functions like TruDensity and TruPGMI. The strategic relationship with RevealDx also presents opportunities for market penetration and product integration. However, the company currently reports a profit margin of -28.0%, indicating ongoing investment in growth and operations, which poses a financial risk. The beta of 1.67 suggests higher volatility compared to the broader market. Sustained investment in R&D and market expansion will be critical for VPAHF to transition towards profitability and capitalize on its high gross margin.

Based on FMP financials and quantitative analysis

VPAHF Key Highlights

Gross Margin of 76.8% demonstrates strong profitability on its software and services.

• Profit Margin of -28.0% indicates the company is currently operating at a loss, likely due to investments in growth and R&D.
• Market Capitalization stands at $188M, reflecting its current valuation as a small-cap healthcare technology firm.
• Beta of 1.67 suggests the stock is more volatile than the overall market, potentially appealing to investors with higher risk tolerance.
• Headquartered in Wellington, New Zealand, with a global operational footprint spanning North America, Asia Pacific, Europe, the Middle East, and Africa, indicating international market reach.

Who Are VPAHF's Competitors?

VPAHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are VPAHF's Key Strengths?

Proprietary AI-powered breast and lung imaging analytics software.

• High gross margin of 76.8% on its software products.
• Comprehensive product suite covering image quality, risk assessment, and patient management.
• Global operational presence across multiple continents.

What Are VPAHF's Weaknesses?

Negative profit margin of -28.0%, indicating unprofitability.

• Reliance on a niche market (breast and lung cancer screening).
• Higher stock volatility with a beta of 1.67.
• Disclosure status on OTC market is 'Unknown,' potentially impacting investor confidence.

What Could Drive VPAHF Stock Higher?

VPAHF catalyst: Continued global expansion of its AI-powered breast and lung imaging analytics software into new and existing markets.

• Further development and integration of its Volpara Science AI platform to enhance diagnostic accuracy and operational efficiency.
• Deepening of strategic partnerships, such as the relationship with RevealDx, to broaden market reach and product offerings.
• Increasing adoption of personalized medicine and risk-based screening protocols, driving demand for Volpara's risk assessment tools.
• Potential improvements in financial performance, specifically moving towards profitability, as investments in growth mature.

What Are the Key Risks for VPAHF?

Negative return on equity (-17.6%) — the business is not currently generating profit on shareholder capital.

• Sustained unprofitability, as indicated by a -28.0% profit margin, requiring continued capital investment.
• Intense competition in the medical imaging analytics market from larger, more established healthcare technology companies.
• Regulatory changes and compliance challenges in the diverse global healthcare markets where it operates.
• Dependence on the adoption rates of AI in diagnostic imaging and the acceptance of its specific software solutions by healthcare providers.
• Risks associated with trading on the OTC market, including lower liquidity, wider bid-ask spreads, and limited public disclosure.

What Are the Growth Opportunities for VPAHF?

• Expansion into Lung Cancer Screening Market: Volpara Lung, a patient management software streamlining lung screening workflow, represents a significant growth opportunity. The global lung cancer screening market is projected to grow, driven by increasing awareness and screening recommendations for high-risk individuals. By leveraging its existing AI and software expertise from breast imaging, Volpara can penetrate this adjacent market. This expansion could tap into a new revenue stream, diversifying its product portfolio and reducing reliance on breast imaging alone. The timeline for this growth is ongoing, as lung screening programs continue to mature and expand globally, particularly in regions with high smoking rates or occupational exposure risks.
• Increased Adoption of AI in Diagnostic Imaging: The broader healthcare industry is rapidly adopting AI for enhanced diagnostic accuracy and operational efficiency. Volpara Science, the AI-based software powering its products, positions the company to capitalize on this trend. As healthcare systems seek to improve early detection rates and optimize resource allocation, sophisticated AI tools like Volpara's, which provide objective assessments of image quality, breast density, and patient risk, become increasingly valuable. This opportunity is ongoing, with market projections indicating substantial growth in AI-driven medical diagnostics over the next decade, as technology matures and regulatory frameworks adapt.
• Global Market Penetration and Geographic Expansion: Volpara currently operates in North America, Asia Pacific, Europe, the Middle East, and Africa. There is substantial opportunity for deeper penetration within these existing markets and expansion into new emerging markets. Many regions are still developing their breast and lung cancer screening infrastructure, presenting a greenfield opportunity for Volpara's software solutions. Strategic partnerships, similar to its relationship with RevealDx, can accelerate market entry and adoption. This growth driver is ongoing, with a long-term horizon as healthcare systems worldwide continue to modernize and invest in advanced diagnostic technologies.
• Enhancing Risk Assessment and Personalized Screening: Volpara Risk and Volpara Risk Pathways, which integrate with Patient Hub to calculate breast cancer risk using TC8 and manage high-risk patients, align with the growing trend towards personalized medicine. As understanding of genetic and lifestyle risk factors for cancer improves, healthcare providers are increasingly moving away from one-size-fits-all screening protocols. Volpara's tools enable more targeted screening, potentially leading to earlier detection in high-risk groups and reduced unnecessary procedures in low-risk individuals. This opportunity is ongoing, driven by clinical guideline updates and the demand for more precise, patient-centric care models.
• Leveraging Clinical Functions for Improved Image Quality: Volpara's clinical functions like TruPGMI (patient positioning and image quality), TruPressure (compression optimization), and TruRadDose (radiation dose analysis) address critical aspects of mammography quality and patient safety. Suboptimal image quality or excessive radiation can lead to missed diagnoses or patient discomfort. By providing objective, AI-driven feedback, these tools help clinics maintain high standards, reduce re-scans, and improve patient experience. As regulatory bodies and accreditation programs emphasize quality metrics, the demand for such tools is expected to rise. This is an ongoing growth opportunity, with a continuous need for quality assurance in diagnostic imaging.

What Threats Does VPAHF Face?

• Intense competition from larger medical imaging companies and other software providers.
• Rapid technological advancements requiring continuous R&D investment.
• Regulatory changes and compliance requirements in global healthcare markets.
• Potential for data security breaches or privacy concerns with patient health information.

What Are VPAHF's Competitive Advantages?

• Proprietary AI-driven algorithms and software, such as Volpara Science, which powers its unique clinical functions like TruDensity and TruPGMI.
• Extensive dataset and clinical validation for its breast imaging analytics, contributing to accuracy and reliability.
• Global operational footprint and established presence in multiple key markets (North America, Europe, Asia Pacific).
• Integrated product suite that addresses multiple aspects of the screening workflow, from image quality to risk assessment and patient communication.

What Does VPAHF Do?

Volpara Health Technologies Limited, incorporated in 2009 and headquartered in Wellington, New Zealand, is a specialized provider of breast imaging analytics software solutions. The company's core mission revolves around leveraging artificial intelligence to enhance the quality and efficiency of breast cancer screening, ultimately aiming for earlier detection and improved patient outcomes. Volpara's product suite is comprehensive, addressing various facets of the screening workflow. Key offerings include Volpara Analytics, a software designed to optimize breast cancer screening operations by providing actionable insights. Volpara Live delivers instant, patient-based image quality feedback, crucial for ensuring diagnostic accuracy at the point of care. Beyond breast screening, the company also offers Volpara Lung, a patient management software that streamlines the workflow for lung screening programs. A significant component of Volpara's portfolio is the Volpara Patient Hub, a customizable mammography reporting and patient communications software that facilitates better engagement and information dissemination. Integrated with Patient Hub is Volpara Risk, which utilizes the TC8 model to calculate a patient's risk of developing breast cancer, enabling more personalized screening protocols. Complementing this is Volpara Risk Pathways, a program specifically designed for identifying and managing high-risk breast cancer screening patients. The Volpara Scorecard provides essential patient breast density and risk insights, supporting improved clinical decision-making. At the technological heart of these products is Volpara Science, an AI-based software platform that powers the entire Volpara ecosystem. The company's clinical functions, such as TruDensity, TruPGMI, TruPressure, and TruRadDose, further illustrate its commitment to precision. TruDensity objectively assesses breast density, a critical factor in cancer risk and screening efficacy. TruPGMI uses AI to automatically evaluate patient positioning and image quality, while TruPressure ensures optimal compression during mammography for quality images with minimal discomfort and radiation. TruRadDose analyzes radiation exposure based on breast density. Volpara Health Technologies operates on a global scale, with its solutions deployed across North America, the Asia Pacific, Europe, the Middle East, and Africa. The company also maintains a strategic relationship with RevealDx, further expanding its reach and capabilities in the diagnostic imaging space. This extensive product range and global presence underscore Volpara's evolution into a key player in healthcare information services, focused on advanced diagnostics.

What Products and Services Does VPAHF Offer?

• Develops AI-powered software for breast imaging analytics.
• Offers Volpara Analytics to optimize breast cancer screening operations.
• Provides Volpara Live for instant patient-based image quality feedback during screenings.
• Markets Volpara Lung, a patient management software for streamlining lung screening workflows.
• Delivers Volpara Patient Hub for customizable mammography reporting and patient communications.
• Integrates Volpara Risk with Patient Hub to calculate breast cancer risk using TC8.
• Offers clinical functions like TruDensity (breast density), TruPGMI (image quality), TruPressure (compression), and TruRadDose (radiation dose analysis).
• Operates globally across North America, Asia Pacific, Europe, the Middle East, and Africa.

How Does VPAHF Make Money?

• Generates revenue primarily through subscription-based software licenses for its analytics and patient management platforms.
• Provides ongoing support and maintenance services for its deployed software solutions.
• Monetizes its AI-powered clinical functions, such as TruDensity and TruPGMI, likely through bundled offerings or add-on modules.
• Engages in strategic partnerships, like with RevealDx, which may involve licensing agreements or joint ventures.

What Industry Does VPAHF Operate In?

Volpara Health Technologies Limited operates within the Medical - Healthcare Information Services industry, a segment experiencing significant growth driven by the digitalization of healthcare and the increasing adoption of artificial intelligence for diagnostics and operational efficiency. The broader market for medical imaging analytics is expanding as healthcare providers seek solutions to improve screening accuracy, reduce costs, and manage patient data more effectively. Volpara positions itself as a specialist in breast and lung imaging analytics, offering AI-powered software that enhances early cancer detection and streamlines clinical workflows. The competitive landscape includes larger medical imaging companies and specialized software providers. Volpara differentiates itself through its focus on specific clinical functions like breast density assessment (TruDensity) and image quality feedback (TruPGMI), aiming to capture market share by offering precise, AI-driven tools that integrate into existing screening programs globally. The trend towards personalized medicine and risk-based screening further underscores the relevance of Volpara's offerings.

Who Are VPAHF's Key Customers?

• Hospitals and healthcare systems offering breast and lung cancer screening services.
• Diagnostic imaging centers and radiology clinics.
• Breast cancer screening programs and research institutions.
• Medical professionals, including radiologists, radiographers, and oncologists.

Return on equity for Volpara Health Technologies Limited stands at -17.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.1%, the inverse of the P/E and a quick read on earnings relative to price.

Volpara Health Technologies Limited (VPAHF) Valuation Context

Valued at $188M, VPAHF is classified as a micro-cap stock.

Company Profile

Volpara Health Technologies Limited operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Wellington, NZ. The company is led by CEO Teri Jo Thomas. VPAHF has traded publicly since 2018.

Volpara Health Technologies Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.60 places it in the grey zone, a middle ground that warrants monitoring.

Wall Street analysts project Volpara Health Technologies Limited revenue of about $53.4M for fiscal 2026, with EPS near $0.03.

VPAHF Financials

VPAHF Latest News

Volpara Health Technologies Limited Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources